RO

Zachariah Reitano knows firsthand what it's like to need medication and not be able to get it easily. At 17, he was diagnosed with a heart condition that affected his sexual health.

Getting treatment as a teenager meant navigating a healthcare system that was slow, expensive, and deeply uncomfortable for something already uncomfortable to talk about. That experience stayed with him.

In 2017, Reitano co-founded Roman — the brand that would become Ro — with Rob Schutz and Saman Rahmanian. The pitch was simple: let men consult with a licensed physician online, get a prescription, and have medication shipped to their door.

No waiting rooms. No insurance headaches.

No face-to-face conversations about things most men would rather not discuss out loud.

They launched with erectile dysfunction treatment first. Not because it was glamorous, but because it was a massive, underserved market where embarrassment was the primary barrier to care.

Men weren't not getting treatment because it wasn't available — they were avoiding the process entirely. Ro removed the friction and built a direct-to-consumer telehealth brand that treated the patient, not just the symptom.

The name Roman was eventually shortened to Ro as the company expanded beyond men's health. What started as a single-condition men's wellness play became a full-stack healthcare company with its own pharmacy network, lab services, and patient platform.

Ro operates as a direct-to-consumer telehealth platform. Here's how it works: a patient comes to the website, answers a health questionnaire, gets connected to a licensed physician in their state, receives a prescription if appropriate, and has medication shipped directly from Ro's own pharmacy network.

The whole thing can happen in under 24 hours.

Patients pay out of pocket. Ro intentionally bypasses traditional insurance, which keeps the process fast and private — two things their customers care about deeply.

Prices are typically competitive with or cheaper than co-pay models, especially for generic medications like sildenafil (the generic version of Viagra).

The business has three interlocking parts. First, the digital front door: the telehealth platform where patients get consultations.

Second, the pharmacy infrastructure: Ro built its own pharmacy network — including acquiring Kit (a pharmacy startup) in 2021 — so they control fulfillment and margins. Third, the data layer: every interaction generates health data that improves the platform, enables follow-up care, and supports subscription-based ongoing treatment.

Subscriptions are the real engine. Patients who start treatment for a chronic condition — ED, hair loss, weight management — don't stop needing medication.

A patient acquired once can generate recurring revenue for years. That's a very different unit economics profile than a typical healthcare visit.

Ro's core product is its telehealth platform — an asynchronous consultation model where patients fill out a detailed health questionnaire, a licensed physician reviews it and prescribes if appropriate, and medication ships within 24–48 hours. No video call required.

No appointment booking. The whole thing is designed to be as frictionless as humanly possible.

Roman is the men's health brand — originally the whole company, now one pillar of it. It covers erectile dysfunction (sildenafil and tadalafil), premature ejaculation, hair loss (finasteride and minoxidil), and general men's health concerns.

Rory is the women's health platform, launched in 2019. It handles menopause symptoms, skin care, sleep, and sexual health for women.

It runs on the same infrastructure as Roman but with entirely different clinical protocols and a different brand voice.

Ro Body is the weight management program — the one that caught fire with the GLP-1 wave. It pairs medication (including compounded semaglutide) with health coaching and lifestyle support.

This has become one of the fastest-growing parts of the business.

Ro Pharmacy is the behind-the-scenes infrastructure that makes everything else work. It's a network of fulfillment pharmacies that Ro either owns or controls, which allows same or next-day shipping and keeps the supply chain in-house.

Ro Labs was launched to bring diagnostic testing into the platform — ordering lab work, interpreting results, and incorporating that data into ongoing care. It closes the loop between telehealth consultation and actual clinical data, which is what turns a telehealth app into something resembling a primary care provider.

Ro's first growth trick was so obvious it's almost embarrassing: they ran ads. Not organic content, not word of mouth — they went straight to Facebook and Google with ads about erectile dysfunction.

In 2017 and 2018, competitors were tiptoeing around the topic. Ro leaned into it.

The result was a flood of traffic from men who'd been quietly searching for exactly this solution and couldn't believe it existed.

The counterintuitive move was building the pharmacy infrastructure in-house instead of outsourcing it. Most telehealth startups hand off fulfillment to third-party pharmacies, which creates delays, quality control issues, and margin leakage.

Ro decided early that if they owned the pharmacy, they owned the experience. That bet paid off — it gave them pricing flexibility, faster shipping, and a vertical integration story that investors loved.

When the COVID-19 pandemic hit in 2020, telehealth went from a niche product to a mainstream expectation overnight. Ro was already built for this.

While traditional healthcare systems scrambled to set up video consultations, Ro had been doing async text-based consultations for three years. The pandemic didn't create Ro's growth — it validated everything they'd already built.

Expansion into women's health under the Rory brand and the launch of Body — their weight management program timed almost perfectly with the rise of GLP-1 drugs like semaglutide — showed they understood that the platform was the product, not any single condition. The GLP-1 wave in particular was a massive tailwind.

When Ozempic became a cultural moment in 2022 and 2023, Ro was already positioned to offer compounded semaglutide to patients who couldn't access or afford the branded version.

The GLP-1 opportunity is also Ro's biggest liability right now. Compounded semaglutide — the generic alternative to Ozempic and Wegovy — became one of Ro's fastest-growing products.

But it exists in a legal gray area. Compounding pharmacies can legally make a drug when there's an FDA-recognized shortage.

The moment Novo Nordisk resolves the Ozempic shortage, compounders like Ro lose the legal basis to sell it. The FDA began cracking down in 2024, and Ro — along with every other telehealth company in the weight loss space — faces a cliff.

Then there's the broader regulatory environment. Telehealth got a lot of regulatory leniency during COVID.

Some of those relaxed rules around prescribing controlled substances and cross-state practice are now tightening back up. Every time a rule tightens, Ro has to adjust its clinical protocols and, sometimes, stop serving patients in certain states.

Competition is brutal and well-funded. Hims & Hers went public via SPAC in 2021 and is a direct competitor for almost every condition Ro treats.

Amazon launched RxPass. CVS and Walgreens both have telehealth ambitions.

Ro built a lead, but it's not a moat — it's a head start, and the gap is closing.

And profitability remains elusive. Customer acquisition costs in digital health are high, and while subscriptions help with LTV, the company has burned significant cash building out its pharmacy infrastructure.

At $876 million raised, they have runway — but the path to sustainable profit isn't obvious yet.

Ro raised its Series A in 2018 from FirstMark Capital, the New York-based firm that also backed Pinterest and Discord. FirstMark getting in early validated the direct-to-consumer telehealth model before it was obvious.

The big moment came with the Series C in 2020 — a $200 million round at a $1.5 billion valuation that made Ro a unicorn. General Catalyst led that round.

General Catalyst has been one of the most aggressive health tech investors in the market, with a portfolio that includes Livongo, Oscar Health, and Stripe. Their backing wasn't just capital — it was a signal that serious healthcare investors believed in the model.

SoftBank led the Series D in 2021, pouring $150 million into the company at a $5 billion valuation. SoftBank's involvement doubled the valuation in under a year.

It also added a strategic pressure: SoftBank's portfolio companies are expected to scale fast and go public eventually. That's still an open question for Ro.

Other investors include TQ Ventures, SignalFire, and Initialized Capital. The investor roster reflects both the venture community's enthusiasm for digital health during 2020–2021 and the specific conviction that owning the pharmacy layer — not just the consultation layer — was the right structural bet.